PMID- 29766376
OWN - NLM
STAT- MEDLINE
DCOM- 20190618
LR  - 20190618
IS  - 1434-9949 (Electronic)
IS  - 0770-3198 (Linking)
VI  - 37
IP  - 9
DP  - 2018 Sep
TI  - Long-term etanercept retention patterns and factors associated with treatment 
      discontinuation: a retrospective cohort study using Canadian claims-level data.
PG  - 2351-2360
LID - 10.1007/s10067-018-4141-z [doi]
AB  - To examine 12-month retention rates over 6 years of etanercept patients in 
      Canada, and to identify factors associated with treatment discontinuation. A 
      retrospective cohort study was conducted using longitudinal prescription drug 
      claims data from IQVIA Private Drug Plan database (PDP), Ontario Public Drug Plan 
      database (OPDP), and Regie de l'assurance maladie du Quebec database (RAMQ). 
      Between 07/2008 and 06/2010, bio-naive patients who initiated etanercept were 
      identified and followed for 72 months. Twelve-month retention rates were 
      estimated in one-year increments and factors associated with time to 
      discontinuation over the 72-month period were identified using a Cox proportional 
      hazards regression model. The study identified 4528 etanercept patients (61% 
      female, 85% rheumatic diseases, and 15% psoriasis). Twelve-month etanercept 
      retention rates increased significantly for patients following their first year 
      on therapy (p < 0.0001), with 66% of patients retained at year 1 vs. 79, 82, 84, 
      83, and 79% at years 2, 3, 4, 5, and 6, respectively. 17.1% (n = 771) of patients 
      were retained for the entire 72-month study. Patients with psoriasis were at 
      increased risk (HR 1.199; p < 0.0001); while public drug coverage plan patients 
      (OPDP HR 0.721; p < 0.0001 and RAMQ HR 0.537; p < 0.0001) were at decreased risk 
      of treatment discontinuation. Twelve-month etanercept retention rates increased 
      significantly for patients following their first year on therapy. Indication and 
      drug coverage plan were associated with patients' time to etanercept 
      discontinuation. With a better understanding of factors associated with 
      retention, programs can be designed to address the specific needs of at-risk 
      groups while supporting patients stable on therapy.
FAU - Khraishi, Majed
AU  - Khraishi M
AD  - Faculty of Medicine, Department of Medicine (Rheumatology), Memorial University 
      of Newfoundland, 120 Stavanger Drive, St. John's, NL, A1A 5E8, Canada. 
      mkhraishi@gmail.com.
FAU - Ivanovic, Jelena
AU  - Ivanovic J
AD  - Health Access and Outcomes, IQVIA, 535 Legget Drive, Kanata, ON, K2K 3B8, Canada.
FAU - Zhang, Yvonne
AU  - Zhang Y
AD  - Health Access and Outcomes, IQVIA, 535 Legget Drive, Kanata, ON, K2K 3B8, Canada.
FAU - Millson, Brad
AU  - Millson B
AD  - Health Access and Outcomes, IQVIA, 535 Legget Drive, Kanata, ON, K2K 3B8, Canada.
FAU - Brabant, Marie-Josee
AU  - Brabant MJ
AD  - Health Access and Outcomes, IQVIA, 535 Legget Drive, Kanata, ON, K2K 3B8, Canada.
FAU - Charland, Katia
AU  - Charland K
AD  - Health Access and Outcomes, IQVIA, 535 Legget Drive, Kanata, ON, K2K 3B8, Canada.
FAU - Woolcott, John
AU  - Woolcott J
AD  - Health Economics and Outcomes Research, Pfizer Inc., 17300 Trans-Canada Highway, 
      Kirkland, QC, H9J 2M5, Canada.
FAU - Jones, Heather
AU  - Jones H
AD  - Inflammation and Immunology, Global Medical Affairs, Pfizer Inc., 500 Arcola 
      Road, F-5303, Collegeville, PA, 19426, USA.
LA  - eng
PT  - Journal Article
DEP - 20180516
PL  - Germany
TA  - Clin Rheumatol
JT  - Clinical rheumatology
JID - 8211469
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - FYS6T7F842 (Adalimumab)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Adalimumab/therapeutic use
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antirheumatic Agents/adverse effects
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Canada
MH  - Child
MH  - Child, Preschool
MH  - Databases, Factual
MH  - Etanercept/*adverse effects
MH  - Female
MH  - Humans
MH  - Immunoglobulin G/adverse effects
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - *Medication Adherence
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Psoriasis/*drug therapy
MH  - Retrospective Studies
MH  - Spondylitis, Ankylosing/*drug therapy
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors
MH  - Young Adult
OTO - NOTNLM
OT  - Ankylosing spondylitis
OT  - Epidemiology
OT  - Psoriasis
OT  - Psoriatic arthritis
OT  - Rheumatoid arthritis
EDAT- 2018/05/17 06:00
MHDA- 2019/06/19 06:00
CRDT- 2018/05/17 06:00
PHST- 2018/02/01 00:00 [received]
PHST- 2018/05/04 00:00 [accepted]
PHST- 2018/04/26 00:00 [revised]
PHST- 2018/05/17 06:00 [pubmed]
PHST- 2019/06/19 06:00 [medline]
PHST- 2018/05/17 06:00 [entrez]
AID - 10.1007/s10067-018-4141-z [pii]
AID - 10.1007/s10067-018-4141-z [doi]
PST - ppublish
SO  - Clin Rheumatol. 2018 Sep;37(9):2351-2360. doi: 10.1007/s10067-018-4141-z. Epub 
      2018 May 16.